Journal
CHINESE MEDICAL JOURNAL
Volume 135, Issue 3, Pages 261-267Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CM9.0000000000001932
Keywords
Antibody-drug conjugate; HER2-positive; Breast cancer; T-DM1; DS-8201
Categories
Funding
- National Natural Science Foundation of China [81874122]
- Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine [2017-I2M-3-004]
Ask authors/readers for more resources
Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs, and have shown potential as a promising treatment option for breast cancer and other tumors.
Antibody-drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high anti-tumor activity of small molecular cytotoxic payloads. The anti-tumor activity of ADCs is mainly achieved by the direct blocking of the receptor by monoclonal antibodies, direct action and bystander effect of cytotoxic drugs, and antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. ADCs have been used in adjuvant therapy and rescue treatment of human epidermal receptor 2 (HER2)-positive breast cancer, greatly improving the prognosis of breast cancer patients. Several ongoing clinical trials of ADC for breast cancer and other solid tumors proved the potential of ADCs will provide more promising treatment options for patients with malignant tumors. This review introduces the mechanism and latest clinical progress of ADC drugs approved for HER2-positive breast cancer to guide clinical practice and conduct research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available